Pharma might negotiate with Trump after all
Back in July, President Trump gave the drug industry an ultimatum: Come up with a way to reduce drug costs in the U.S. or deal with a policy that pegs prices to what other countries pay. After some intense debate over whether to respond at all, the trade group PhRMA has a few counteroffers.
As STAT’s Nicholas Florko reports, lobbyists are circulating a pair of policy proposals that could be offered as a trade with Trump to avoid a so-called Most Favored Nations rule, which would require drug makers sell injectable drugs for the lowest price they offer similar countries. According to a summary obtained by STAT, PhRMA’s proposals would expand discounts offered to the government and save the U.S. $100 billion over 10 years.
What remains unclear is whether the industry is going to pitch its ideas to the White House, much less whether Trump would find them satisfactory.
Read more.
As STAT’s Nicholas Florko reports, lobbyists are circulating a pair of policy proposals that could be offered as a trade with Trump to avoid a so-called Most Favored Nations rule, which would require drug makers sell injectable drugs for the lowest price they offer similar countries. According to a summary obtained by STAT, PhRMA’s proposals would expand discounts offered to the government and save the U.S. $100 billion over 10 years.
What remains unclear is whether the industry is going to pitch its ideas to the White House, much less whether Trump would find them satisfactory.
Read more.
.png)
No hay comentarios:
Publicar un comentario